Evidence map›Paper›PMID 39927213›Full record

ArticlePhysics and imaging in radiation oncology2025

New rectum dose surface mapping methodology to identify rectal subregions associated with toxicities following prostate cancer radiotherapy.

Artemis Bouzaki, Dylan Green, Marcel van Herk, Jane Shortall, Tanuj Puri, Sarah Kerns, David Azria, Marrie-Pierre Farcy-Jacquet, Jenny Chang-Claude, Ananya Choudhury and 16 more

Abstract read
In one paragraph

Article in Physics and imaging in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Systematic review of artificial intelligence in brachytherapy.Journal of contemporary brachytherapy · 2026
    Review
  3. Integration of Dose Surface Maps and Genetic Data Identifies the Lower Posterior Rectum as a Key Region for Toxicity after Prostate Cancer Radiotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Artemis BouzakiDivision of Cancer Sciences, University of Manchester, Manchester, the United Kingdom of Great Britain and Northern Ireland.
Dylan GreenDepartment of Engineering Science, University of Oxford, Oxford, the United Kingdom of Great Britain and Northern Ireland.
Marcel van HerkDivision of Cancer Sciences, University of Manchester, Manchester, the United Kingdom of Great Britain and Northern Ireland.
Jane ShortallDivision of Cancer Sciences, University of Manchester, Manchester, the United Kingdom of Great Britain and Northern Ireland.
Tanuj PuriDivision of Cancer Sciences, University of Manchester, Manchester, the United Kingdom of Great Britain and Northern Ireland.
Sarah KernsMedical College of Wisconsin, Milwaukee, WI, USA.
David AzriaFederation Universitaire d'Oncologie Radiothérapie d'Occitanie Méditerranée, Univ Montpellier, INSERM U1194 IRCM, Institut du Cancer Montpellier (ICM), Montpellier, France.
Marrie-Pierre Farcy-JacquetFederation Universitaire d'Oncologie Radiothérapie d'Occitanie Méditerranée, Institut du Cancer Du Gard (ICG), CHU Carémeau, Nîmes, France.
Jenny Chang-ClaudeGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.
Ananya ChoudhuryDivision of Cancer Sciences, University of Manchester, Manchester, the United Kingdom of Great Britain and Northern Ireland.
Alison DunningCentre for Cancer Genetic Epidemiology, Strangeways Research Laboratory, University of Cambridge, Cambridge, the United Kingdom of Great Britain and Northern Ireland.
Maarten LambrechtKU Leuven, Leuven, Belgium.
Barbara AvuzziDepartment of Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Dirk De RuysscherDepartment of Radiation Oncology (Maastro), Maastricht University Medical Center, GROW School, Maastricht, the Netherlands.
Petra SeiboldGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.
Elena SperkDepartment of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Christopher TalbotDepartment of Genetics & Cancer Sciences, University of Leicester, the United Kingdom of Great Britain and Northern Ireland.
Ana VegaInstituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Liv VeldemanGhent University Hospital, Belgium.
Adam WebbDepartment of Genetics & Cancer Sciences, University of Leicester, the United Kingdom of Great Britain and Northern Ireland.
Barry RosensteinDepartments of Radiation Oncology & Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, NY, USA.
Catharine M WestTranslational Radiobiology Group, Division of Cancer Sciences, University of Manchester, The Christie NHS Foundation Trust, Manchester, the United Kingdom of Great Britain and Northern Ireland.
Eliana GioscioData Science Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Tiziana RancatiData Science Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Eliana Vasquez OsorioDivision of Cancer Sciences, University of Manchester, Manchester, the United Kingdom of Great Britain and Northern Ireland.
Alan McWilliamDivision of Cancer Sciences, University of Manchester, Manchester, the United Kingdom of Great Britain and Northern Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Growing evidence suggests that spatial dose variations across the rectal surface influence toxicity risk after radiotherapy. Existing methodologies employ a fixed, arbitrary physical extent for rectal dose mapping, limiting their analysis. We developed a method to standardise rectum contours, unfold them into 2D cylindrical surface maps, and identify subregions where higher doses increase rectal toxicities. Materials and methods: Data of 1,048 patients with prostate cancer from the REQUITE study were used. Deep learning based automatic segmentations were generated to ensure consistency. Rectum length was standardised using linear transformations superior and inferior to the prostate. The automatic contours were validated against the manual contours through contour variation assessment with cylindrical mapping. Voxel-based analysis of the dose surface maps for the manual and automatic contours against individual rectal toxicities was performed using Student's t permutation test and Cox Proportional Hazards Model (CPHM). Significance was defined by permutation testing. Results: Our method enabled the analysis of 1,048 patients using automatic segmentation. Student's Conclusion: We developed a methodology that unfolds the rectum to a 2D surface map. The lower posterior was significant for clinician-reported proctitis and patient-reported bowel urgency, suggesting that reducing the dose in the region could decrease toxicity risk.

Indexed as

Dose surface mapNormal tissue toxicityProstate cancerRadiotherapyRectum mapping

Identifiers

PMID39927213
PMCPMC11803856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.